Veracyte (NASDAQ:VCYT) Issues Earnings Results

Veracyte (NASDAQ:VCYT) released its earnings results on Tuesday. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.18, Briefing.com reports. Veracyte had a net margin of 12.83% and a return on equity of 8.05%. The company had revenue of $139.07 million for the quarter, compared to the consensus estimate of $130.36 million. During the same period in the prior year, the company posted $0.31 EPS. The company’s revenue was up 21.5% compared to the same quarter last year.

Here are the key takeaways from Veracyte’s conference call:

• Veracyte delivered a strong Q1 with $139.1M total revenue (up 21% YoY), testing revenue of $135.1M (+26%), adjusted EBITDA of $42.8M (30.8% margin), and raised 2026 revenue guidance to $582M–$592M with adjusted EBITDA >26%.
• The Decipher franchise remains the primary growth engine—~28,000 tests in Q1 (+24% YoY), ~30% growth in high‑risk categories, and multiple Phase III studies (GUIDANCE, ENZAMET, PredictRT) and NCCN inclusion supporting longer‑term uptake.
• Afirma volumes improved to ~17,200 tests (+12% YoY) after the full transition to the V2 transcriptome, which materially reduced no‑result rates (adding ~400 bps to volume) and contributed to margin improvement.
• Two upcoming launches—Prosigna LDT (OPTIMA data at ASCO; commercial mid‑year) and TruMRD in muscle‑invasive bladder cancer (launch by end of Q2)—are positioned as major catalysts, but commercial impact is contingent on trial readouts, guideline/reimbursement decisions and adoption.
• Strong cash generation ($35.2M from operations; $439.1M cash/short‑term investments) and improved gross margins (non‑GAAP 75.7%) provide flexibility to fund R&D, commercial scale-up and selective M&A aligned with the company’s oncology focus.

Veracyte Stock Performance

NASDAQ VCYT traded up $8.63 during trading hours on Wednesday, reaching $41.60. 1,746,899 shares of the company’s stock were exchanged, compared to its average volume of 880,250. The company’s 50-day moving average is $33.33 and its two-hundred day moving average is $38.16. Veracyte has a one year low of $22.61 and a one year high of $50.71. The company has a market capitalization of $3.32 billion, a price-to-earnings ratio of 50.00 and a beta of 1.89.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on VCYT shares. Canaccord Genuity Group set a $42.00 target price on shares of Veracyte in a research report on Wednesday. UBS Group reiterated a “buy” rating and issued a $52.00 price target on shares of Veracyte in a research report on Wednesday. Jefferies Financial Group began coverage on shares of Veracyte in a research report on Monday, April 13th. They issued a “buy” rating and a $45.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $48.00 price target on shares of Veracyte in a research report on Wednesday, April 1st. Finally, Zacks Research downgraded shares of Veracyte from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 12th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Veracyte presently has an average rating of “Hold” and a consensus target price of $44.83.

Veracyte News Summary

Here are the key news stories impacting Veracyte this week:

• Positive Sentiment: Q1 beat on both EPS and revenue — Veracyte reported $0.52 EPS vs. consensus $0.34 and revenue of $139.1M (up 21.5% YoY), a clear short-term catalyst driving optimism. Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Raised FY2026 revenue outlook — Veracyte updated revenue guidance to $582M–$592M vs. the $576.5M consensus, signaling better-than-expected top-line momentum. Veracyte Announces First Quarter 2026 Financial Results
• Positive Sentiment: Strong product-line performance — Management said Decipher and Afirma volumes surpassed expectations and exceeded profitability targets, supporting margin and revenue improvement. Company Press Release
• Positive Sentiment: Analyst sentiment and upside — Several analysts have raised forecasts/targets; one roundup highlights ~39% average upside from price targets, which can pull momentum into the stock. Wall Street Analysts Think Veracyte Could Surge
• Neutral Sentiment: TrueMRD launch is a watched catalyst — Investors are awaiting details/timing for TrueMRD (a potential recurring-revenue product); positive launch details could extend gains, but timing/uptake remain uncertain. Veracyte earnings loom: Investors watch for TrueMRD launch details
• Neutral Sentiment: Earnings call and slide deck available — The transcript and slides provide more color on margin drivers and product performance for those modeling forward results. Earnings Call Transcript Slide Deck
• Negative Sentiment: Valuation and volatility risk — The shares trade at a relatively high P/E (~48.6) and carry a beta near 1.9, so upside could be met with sharp swings if growth expectations slip. (Background market data)
• Negative Sentiment: Guidance gaps — The company emphasized revenue guidance but did not provide specific EPS guidance in its update, leaving some short-term earnings visibility incomplete. Earnings Release and Materials

Insiders Place Their Bets

In related news, CEO Marc Stapley sold 45,523 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $35.97, for a total transaction of $1,637,462.31. Following the completion of the sale, the chief executive officer directly owned 357,554 shares of the company’s stock, valued at approximately $12,861,217.38. This represents a 11.29% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Annie Mcguire sold 6,658 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $35.55, for a total value of $236,691.90. Following the sale, the senior vice president directly owned 94,706 shares of the company’s stock, valued at approximately $3,366,798.30. The trade was a 6.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 75,782 shares of company stock valued at $2,722,097 in the last quarter. 1.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Veracyte

Several hedge funds have recently made changes to their positions in the business. Pacer Advisors Inc. grew its stake in shares of Veracyte by 229.1% during the 4th quarter. Pacer Advisors Inc. now owns 10,280 shares of the biotechnology company’s stock worth $433,000 after acquiring an additional 7,156 shares in the last quarter. Corient Private Wealth LLC bought a new position in shares of Veracyte during the 4th quarter worth approximately $5,475,000. Fuller & Thaler Asset Management Inc. bought a new position in shares of Veracyte during the 4th quarter worth approximately $58,158,000. Empowered Funds LLC bought a new position in shares of Veracyte during the 4th quarter worth approximately $42,000. Finally, XTX Topco Ltd bought a new position in shares of Veracyte during the 4th quarter worth approximately $962,000.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.